Zhi Tong Cai Jing·2026-03-23 05:20Core Viewpoint - China National Pharmaceutical Group (国药控股) reported a slight decline in revenue but an increase in net profit, demonstrating resilience and effective cash flow management amid market fluctuations [3][4]. Financial Performance - The company achieved revenue of RMB 575.168 billion for the year ending December 31, 2025, a year-on-year decrease of 1.6% [3]. - Net profit attributable to shareholders was RMB 7.155 billion, reflecting a year-on-year increase of 1.5% [3]. - Earnings per share were RMB 2.29, with a proposed final dividend of RMB 0.69 per share [3]. Operational Efficiency - The overall expense ratio decreased by 0.25 percentage points year-on-year, effectively offsetting the decline in gross profit [3]. - Operating cash flow recorded a net inflow of RMB 14.138 billion, an increase of RMB 2.592 billion compared to the previous year, indicating strong cash flow management [3]. - The accounts receivable growth rate significantly narrowed, showcasing the effectiveness of special governance measures [3]. Business Segments - The pharmaceutical distribution segment accounted for 72.79% of total revenue, a decrease of 0.37 percentage points year-on-year [4]. - The medical device distribution segment represented 19.32% of total revenue, with a slight decline of 0.09 percentage points [4]. - The pharmaceutical retail segment increased its revenue share to 6.42%, up by 0.50 percentage points year-on-year [4]. Strategic Focus - The company aims to prioritize high-quality development, assess regional market conditions, and expand market share through reform and innovation [4].